Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: J Nucl Med. 2013 Jul 19;54(9):1621–1629. doi: 10.2967/jnumed.112.118539

Figure 2.

Figure 2

(A) Biodistribution of 64Cu-DOTA-cetuximab in HCT116 +/+ tumor–bearing nude mice. Data are presented as percentage injected dose per gram (%ID/g) ± SD (n = 5 for each time point). (B) One milligram of unlabeled cetuximab was injected to each mouse 24 h before administration of radiotracer to block specific uptake of 64Cu-DOTA-cetuximab (P < 0.001). (C) Mice bilaterally implanted with both HCT116 +/+ and HCT116 −/− tumors showed tumor uptake to be similar (P = 0.07 at 24 h after injection, P = 0.8 at 72 h after injection).